tirzepatide helps with MASH (aka NASH)
Tirzepatide, the combo of a potent glucagon-like peptide-1 receptor agonist (GLP-1) plus a glucose-dependent insulinotropic polypeptide (GIP) agonist, was found to be highly effective in patients with metabolic dysfunction-associated steatohepatitis (MASH): see NASH tirzepatide NEJM2024 in dropbox, or DOI: 10.1056/NEJMoa2401943) Details : -- 190 participants who had biopsy confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis were randomized in a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial to tirzepatide 5 mg, 10 mg or 15 mg versus placebo subcutaneously weekly for 52 weeks -- mean age 54, 57% female, 86% white/12% Asian/36% Latino, body weight 100 kg/BMI 36 -- type II diabetes in 58% -- liver fibrosis stage: F2 in 43%/F3 in 57%; NAFLD activity score 5.3 (unweighted sum of scores for steatosis, lobular inflammation, and hepatocellular ballooning), ALT 62, AST 51, A1c 6.5%, liver fat con...